title: Biphasic vesicles for topical delivery of interferon alpha in human volunteers and treatment of patients with human papillomavirus infections.
abstract: PURPOSE. Topical biphasic vesicle delivery system encapsulating interferon alpha (IFN α) was developed as an alternative to injections used to treat human papillomavirus (HPV) infections. METHODS. Biphasic lipid vesicles encapsulating increasing doses of IFN α (biphasic IFN α) were characterized for encapsulation efficiency, size, zeta potential and vesicle structure by centrifugation, dynamic light scattering, confocal microscopy and small-angle x-ray scattering. Biphasic IFN-α delivery into human skin in vivo and topical efficacy in patients with genital warts were evaluated. RESULTS. Average encapsulation efficiency of IFN α was 81-91%. The average particle size was 1000-1100 nm and zeta potential +70 to +78 mV. After application of 5, 15 and 40MU/g biphasic IFN α formulation in a topical patch on the upper inner arm in healthy volunteers, skin IFN α levels increased to 120±30, 380±60 and 400±80 IU/mg protein in skin homogenates (n=5, 5, and 7), respectively. Topical application of biphasic IFN α (1 MU/dose) twice daily for two weeks in a pilot study with 12 patients with external condylomata acuminata resulted in a decrease in lesion size, in 2',5'-oligoadenylate synthetase activity and in tissue viral load. CONCLUSIONS. Biphasic vesicles delivered clinically significant levels of IFN α across intact human skin and elicited marked therapeutic effect in patients.
authors.affiliation: School of Pharmacy, University of Waterloo, Waterloo, ON, Canada. foldvari@uwaterloo.ca
authors.forename: Marianna
authors.initials: M
authors.lastname: Foldvari
authors.forename: Ildiko
authors.initials: I
authors.lastname: Badea
authors.forename: Praveen
authors.initials: P
authors.lastname: Kumar
authors.forename: Shawn
authors.initials: S
authors.lastname: Wettig
authors.forename: Ravinder
authors.initials: R
authors.lastname: Batta
authors.forename: Martin J
authors.initials: MJ
authors.lastname: King
authors.forename: Zhihong
authors.initials: Z
authors.lastname: He
authors.forename: Emmanuel
authors.initials: E
authors.lastname: Yeboah
authors.forename: Kimberly
authors.initials: K
authors.lastname: Gaspar
authors.forename: Peter
authors.initials: P
authors.lastname: Hull
authors.forename: Neil H
authors.initials: NH
authors.lastname: Shear
mesh_terms: D015088:2',5'-Oligoadenylate Synthetase / Q000378:metabolism; D000287:Administration, Topical; D000293:Adolescent; D000328:Adult; D003218:Condylomata Acuminata / Q000188:drug therapy* / Q000378:metabolism / Q000821:virology; D005260:Female; D052140:Human papillomavirus 11 / Q000302:isolation & purification; D052163:Human papillomavirus 6 / Q000302:isolation & purification; D006801:Humans; D016898:Interferon-alpha / Q000008:administration & dosage* / Q000097:blood / Q000737:chemistry* / Q000493:pharmacokinetics; D008081:Liposomes / Q000008:administration & dosage / Q000737:chemistry / Q000378:metabolism; D008297:Male; D008875:Middle Aged; D010316:Particle Size; D010865:Pilot Projects; D012867:Skin / Q000187:drug effects / Q000201:enzymology / Q000378:metabolism; D019562:Viral Load / Q000187:drug effects; D055815:Young Adult
chemical_list: D016898:Interferon-alpha; D008081:Liposomes; D015088:2',5'-Oligoadenylate Synthetase